Kunitz type protease inhibitor from the canine tapeworm as a potential therapeutic for melanoma

Shiwanthi L. Ranasinghe 1*, Vanessa Rivera 1, Glen M. Boyle 2 & Donald P. McManus 1

Modulating the tumor microenvironment to promote an effective immune response is critical in managing any type of tumor. Melanoma is an aggressive skin cancer and the incidence rate is increasing worldwide. Potent protease inhibitors have recently been extensively researched as potential therapeutic agents against various cancers. EgKI-1 is a potent Kunitz type protease inhibitor identified from the canine tapeworm Echinococcus granulosus that has shown anti-cancer activities in vivo. In this study we show that EgKI-1 significantly reduced the growth of melanoma in the B16-F0 mouse model and was not toxic to normal surrounding tissue. Moreover, EgKI-1 treatment significantly reduced survivin expression levels and increased the CD8+ T cell population in draining axillary lymph nodes. Therefore, EgKI-1 potentially reduces tumor growth by inducing apoptosis and modulating the tumor microenvironment, and has potential for development as an intra-lesional treatment for melanoma.

Australia and New Zealand have the world’s highest incidence rates for melanoma. It is the third most common cancer diagnosed in Australians and accounts for 9–12% of all new recorded cancers diagnosed 1. In total, 10% of people diagnosed with melanoma have life-threatening metastasis and tissue invasion even after the primary melanoma is surgically removed. The use of combined targeted therapies with surgery still remains inadequate and further research to investigate new treatments is vital.

EgKI-1, identified from the tapeworm Echinococcus granulosus, is a potent neutrophil elastase (NE) inhibitor 2 that was shown to significantly inhibit breast cancer growth in the MDA-MB-231 mouse model 3. NE secreted by neutrophils in the tumor microenvironment has been shown to promote tumor proliferation as well as reducing the activity of CD8+ T cells 4. A preliminary study we undertook showed EgKI-1 inhibited human melanoma cell line (CJM) in vitro 3; a result which led us to undertake further investigation using the B16-F0 murine tumour cell line commonly used as a research model in C57BL/6 mice to study human skin cancers 5.

Lymph nodes, which contain lymphoid cells, are positioned throughout the body and play a crucial role in the immune system 6. Tumor draining lymph nodes (TDLNs) induce anti-tumor T cell responses 6; however there is a high susceptibility to melanoma induced suppression of CD8+ T cells 7. Investigation of immune cells in the TDLNs can lead to a better understanding of the mechanisms involved in cancer progression and/or the development of improved cancer treatments.

In this study we determined the effect of EgKI-1 on lymphoid cells and innate cells in the spleen, axillary lymph nodes and tumor tissue using flow cytometry analysis. Local tumor treatment is particularly advantageous in the case of melanoma due to the low dose needed, the resulting decreased toxicity, and in minimising the risk of auto-immunity 6.8. Furthermore, local targeting can overcome tumor-mediated immune cell suppression by activating robust anti-tumor T cell responses.

In addition, we investigated the modulation of different proteins at the mRNA level following EgKI-1 treatment. These included survivin, an apoptotic and mitotic regulator, that is overexpressed in melanoma and promotes melanoma metastasis 9, matrix metalloproteins (MMPs), proteases that facilitate invasion, metastasis and regulate tumor cell proliferation and apoptosis 10, and Bcl-2 (B-cell lymphoma 2), another regulator of apoptosis 11.

Results
We assessed the potential of EgKI-1 as an anti-cancer agent for the treatment of melanoma using the B16-F0 mouse model. EgKI-1 inhibited the growth of B16-F0 cells in a dose-dependent manner in vitro (Fig. 1A) with an IC50 of 53.24 nM (Fig. 1B).
In the \textit{in vivo} mouse model of melanoma, intrallesional treatment of established tumors with 1.125 \(\mu\)M EgKI-1 significantly slowed melanoma growth compared to the control group with a percentage tumor growth reduction of 68\% (Fig. 2).

Fluorescence-activated cell sorting (FACS) analysis of various cell surface markers was carried out (Supplementary Fig. 1). The results showed that, 7 days after EgKI-1 treatment, the percentage of CD8\(^+\) killer (cytotoxic) T cells present in axillary LNs was significantly lower in the EgKI-1 treated mice compared with the control group. This result favorably indicates improved drainage of CD8\(^+\) cells to the tumor tissue (Fig. 3A). However, there was no significant difference between the levels of CD4\(^+\) cells in control- and EgKI-1-treated mice (Fig. 3B).

Considering innate immune cells there was a significant increase in the number of macrophages in the tumor tissue of EgKI-1 treated mice compared with the control mice (Fig. 3C). No significant differences were apparent in cytokine expression in the tumor tissue of treated and control mice determined using the Cytometric Bead Array (CBA) mouse Th1/Th2/Th17 cytokine kit (data not shown).

There was a significant reduction in Ki67 expression (Fig. 4A–C) in EgKI-1-treated tumor tissue compared with the controls indicating significantly less proliferation of melanoma cells in treated mice. Similarly, a significant increase of caspase-3 was evident in melanoma harvested from mice treated with EgKI-1 compared to controls (Fig. 4D–F). Hematoxylin & Eosin staining of EgKI-1-treated and control tumor sections indicated there was neither acute toxicity on tumor cells 24 hours after treatment nor toxicity after 7 days (Supplementary Fig. 2), indicating that EgKI-1 could be used as a therapeutic without adversely affecting normal surrounding cells.

qPCR analysis was carried out to investigate the role of EgKI-1 on different gene expressions mainly related to tumor growth. According to the results, EgKI-1 treatment significantly inhibited the expression of survivin in B16-F0 cells compared with the control non-treated cells (Fig. 5).

**Figure 1.** (A) Inhibition of the growth of B16-F0 cells \textit{in vitro} with increasing concentrations of EgKI-1. (B) Inhibition curve of B16-F0 cells showing an IC\(_{50}\) of 53.24 nM. N = 3.

**Figure 2.** Intrallesional EgKI-1 treatment prevents melanoma growth. (A) Melanoma growth in control and EgKI-1 treated mice over time. Intrallesional EgKI-1 treatment (1.125 \(\mu\)M) was administered at 2, 4 and 6 days (B) Image showing the sizes of tumors in four of control and (C) treated mice at the end of the experiment ("a" indicates length and "b" indicates width). *For 0.005 \(\leq p < 0.05\), ****for \( p < 0.0001\) according to 2-way ANOVA, with 95\% confidence interval (CI). N = 6 in each group and experiments were repeated in duplicate.
Discussion

The results reported here indicate that EgKI-1 treatment was able to significantly decrease the growth in vivo of invasive B16-F0 melanoma in mice. Targeting the tumor microenvironment and TDLNs locally can significantly improve anti-tumor immunological processes. Furthermore, local administration can significantly reduce possible toxicity and autoimmunity caused by systemic administration.

Histological analysis of tumor sections indicated that no acute toxicity was generated by the local administration of EgKI-1. Survivin, which is an apoptotic and mitotic regulator, is usually overexpressed in melanoma. Research to date strongly supports a direct role for survivin in tumor metastasis. Overexpression of survivin protects melanoma cells and survivin suppression is essential for EgKI-1 induced melanoma apoptosis. According to the ICH analysis EgKI-1 treated tumor sections express significantly higher levels of caspase-3, indicating melanoma cell apoptosis. Therefore, EgKI-1 not only directly induces tumor cell apoptosis but also indirectly via survivin suppression and thus shows promise as a potential new treatment against melanoma.

Ki67 staining indicated most of the melanoma cell proliferations were arrested, releasing molecules such as damage associated molecular patterns (DAMPs)/alarmins which promote and exacerbate the inflammatory response. Tumor-resident CD8+ T cells are associated with improved survival of melanoma patients. On the other hand, CD8+ cytotoxic T cells drain into the tumor from the axillary lymph node, as the TDLN for the melanoma. It has previously been shown that activated T cells in TDLNs of melanoma patients resulted in preferential apoptosis of human cancer cell lines. A previous study showed that purified NE inhibits the transendothelial migration of T lymphocytes. Accordingly, NE inhibition by EgKI-1 may increase T cell migration to tumors, thereby facilitating an attack on tumor cells and favourably modulating the tumor microenvironment. However, more research is needed to confirm this feature in vivo. Macrophages in tissues arise from monocytes and have strong phagocytic potential. Tumor-associated macrophages (TAMs) are key antigen presenting cells and have, apparently paradoxical properties, with the ability to both reduce and promote tumor growth. However, if properly instructed, macrophages can mediate robust anti-tumor responses including eliminating malignant cells, inhibiting angiogenesis and depleting fibrosis. EgKI-1 treatment possibly activates macrophages of the M1 phenotype to induce anti-tumor mechanisms.

Figure 3. Percentage of T cells and innate cells in different tissues of control and EgKI-1 treated mice. (A) CD4+ and (B) CD8+ cells in spleen, lymph node and tumor tissue and (C) innate cells in tumor tissue after 7 days post-treatment with EgKI-1 (1.125 µM). For 0.005 ≤ p < 0.05, 2-way ANOVA test with 95% CI. N = 6 in each group and experiments were repeated in duplicate.
In conclusion, EgKI-1 has the potential to reshape immune regulation in tumors, induce apoptosis and inhibit cell proliferation leading to tumor growth inhibition. Thus, EgKI-1 is a promising molecule to develop as a topical treatment for melanoma. Additional studies should be undertaken with the EgKI-1 protein to further evaluate its potential to promote an inflammatory response as well as determining the mechanisms of direct cancer cell killing by this potent neutrophil elastase inhibitor.

Methods

B16-F0 cell growth analysis. Recombinant EgKI-1 protein was expressed and purified in yeast as described. B16-F0 cells were cultured in complete media (RPMI-1640 supplemented with 10% (v/v) heat-inactivated fetal calf serum (Thermo Fisher Scientific, Waltham, USA), 3 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)), 100 U/ml penicillin and 100 μg/ml streptomycin (Thermo Fisher Scientific).
Cultured cells were routinely checked for mycoplasma infection by a specific PCR-based assay and were always negative.

The effects of EgKI-1 treatment on growth and migration of B16-F0 cells was assessed by Incucyte cell growth assay. The experiment was repeated three times and the IC50 (the concentration of EgKI-1 needed to inhibit cell growth by 50%) value was calculated using "log (inhibitor) vs. response - Variable slope (four parameters)" under nonlinear regression analysis in GraphPad Prism 7 software.

**In vivo mouse model.** B16-F0 cells were cultured and collected by trypsinization. After 3 washes with PBS, to remove any traces of medium, 8 × 10⁵ cells were suspended in 50 μl PBS. Then, 7–8 weeks old female C57BL/6 mice (7 each in the control and treatment groups) were injected with B16-F0 cells (8 × 10⁵ cells per mouse) subcutaneously into the dorsal flank region. Mice were carefully monitored and tumour size was measured by digital Vernier calliper every other day according to the formula, a × b × h × 0.5, where "a" the length and "b" the measured breadth of the tumor. When the tumour volume reach 50 mm³, intra-tumour EgKI-1 treatment (80 μg in 50 μl per mouse) commenced and was repeated every other day. The control group was treated with 50 μl buffer (150 mM NaCl, 20 mM Tris, pH 7). 24 hours after the initial treatment 3 mice from each group were sacrificed to check acute toxicity by analysing tumor histology as later described. Mice were also assessed using an approved clinical distress score sheet over the course of the experiment (Table 1). Scores for each parameter were summed to give a possible total of 8. Less than 3 was considered a mild clinical score, between 3–6 a moderate and over 6 was considered severe. Experimentation on an individual mouse was terminated when an unacceptable clinical score (>6) was reached, or the cumulative tumor burden of the animal exceeded 1000 mm³.

Mice were humanely euthanized by exposure to carbon dioxide at the end of the experiment and samples were subjected to assess histology and immune responses. The experiment was repeated twice.

The mean reduction in tumour growth was calculated according to the formula:

\[
\text{Mean reduction in tumour growth} = \frac{\text{mean tumour volume in control group} - \text{mean tumour volume in treated group}}{\text{mean tumour volume in control group}} 
\times 100
\]

Results were analysed using GraphPad Prism software with 2-way ANOVA.

**Histological analysis.** Histological analysis of tumor sections from paraffin blocks, stained for hematoxylin and eosin (H&E), and the proliferation marker Ki67 were carried out as described previously. Ki67 is a nuclear protein that is expressed in proliferating cells and is a recognized marker for cell proliferation in solid tumors. Caspase-3 is an apoptosis marker of cells undergoing apoptosis and the immunohistochemistry protocol used in this study labels cells with activated caspase-3 presence. Briefly, histological melanoma sections (3–4 μm) of control and EgKI-1-treated mice were affixed to positively charged adhesive slides and air-dried overnight at 37°C. Sections were then dewaxed and rehydrated through descending graded alcohols to Tris-buffered saline (TBS), pH 7.6, followed by incubation in 2.0% (v/v) H₂O₂ in PBS for 10 minutes to block the endogenous peroxidase activity. Slides were then subjected to an oxidizing step with 0.3% (w/v) aqueous potassium permanganate and 3.0% (w/v) aqueous oxalic acid to bleach melanin, which can obscure the caspase-3 signal. A heat antigen retrieval step was then carried out with Tris/EDTA buffer pH 8.8 for 15 minutes at 105°C using a Biocare Medical Decloaking Chamber. Normal goat serum (10%) was then applied for 30 min and rabbit anti-cleaved Caspase-3 antibody (1:100) (Biocare Medical) applied for 2 hours at room temperature. Following 3 washes with TBS, an anti-rabbit MACH1 Universal secondary antibody (Biocare Medical) was applied for 30–45 minutes. After another 3 washes with TBS, color was developed with 3,3′-diaminobenzidine (DAB) for 5 to 10 minutes. Sections were then washed using gently running tap water for 5–10 minutes to remove excess chromogen and lightly counterstained in haematoyxlin, then dehydrated through ascending graded alcohols, cleared in xylene, and mounted using DePeX.

Staining of the slides was carried out in the Histology Facility at QIMR Berghofer Medical Research Institute. Stained slides were scanned at 40× magnification with an Aperio Scanscope XT slidescanner and digital images were analyzed with ImageScope viewing software. The Aperio nuclear algorithm, which is based on the spectral differentiation between brown (positive) and blue counter staining, was used for analysis of Ki67 and caspase-3 signals. Total percentage positivity for each slide was then calculated and statistically analysed using GraphPad Prism software.

**Analysis of immune reactions.** Single cell suspensions were made from spleen and axillary lymph nodes. Isolated tumor tissue was filtered through 70 μm filter and subjected to magnetic isolation of immune cells using CD45 MACS microbeads according to manufacturer's instructions (Miltenyi Biotech, Macquarie Park, NSW, Australia). Single cells were then stained to analyse lymphocytes (CD8, CD4 and B cells) and innate cells

| Criteria                  | Grade 0 | Grade 1 | Grade 2 |
|---------------------------|---------|---------|---------|
| Weight loss               | <10%    | >10 to <25% | >25%    |
| Posture                   | Normal  | Hunching only at rest | Severe hunching impairment |
| Activity                  | Normal  | Mild to moderately decreased | Stationary unless stimulated |
| Fur texture               | Normal  | Mild to moderate ruffling | Severe ruffling/ poor grooming |

Table 1. Clinical scoring for Drug Treated and Tumor Bearing Mice.
A 6 well plates and treated with EgKI-1 at a concentration of 1.125 μM to determine the role of EgKI-1 treatment on gene expression in melanoma cells. B16-F0 cells were grown to 70% confluency in 6 well plates and treated with EgKI-1 at a concentration of 1.125 μM. Cells were then incubated for 30 min on ice in the dark followed by a washing step before they were fixed in cytotox buffer (BD Biosciences). After 20 min incubation on ice, cells were washed with FACS buffer (200 μl of PBS + 2% fetal calf serum (FCS)) and resuspended in 200 μl of FACS buffer. Stained samples were analysed using a 4-laser LSR Fortessa (BD Biosciences) and analysed with FACS Diva and FlowJo software for the analysis. Debris was excluded based on size (forward scatter, FSC) and complexity (side scatter, SSC). Doubles and triplets were further excluded based on FSC height and FSC area. Viable cells which were negative for the FVS780 were then analysed to identify different cell populations as described.

Serum was separated from mouse blood samples collected by heart puncture at the termination of each mouse experiment. Samples were then used to determine cytokine levels using a Cytometric Bead Array (CBA) mouse Th1/Th2/Th17 cytokine kit (BD Biosciences) which measures IL-2, IL-4, IL-6, IFN-γ, TNFα, IL-17A and IL-10 levels in a single sample. The sensitivity of the kit ranges from 5 to 20 pg/ml depending on the cytokine measured.

| Gene     | Forward primer | Reverse primer         |
|----------|----------------|------------------------|
| MMP-2    | GACGGAATGGACGGAACCTC | ACTTCACAGGACCACCTT |
| MMP-14   | CGGAGGTGGCCCATGGCATC | CTCGGCAAGGTCAAATGGG |
| Bcl-2    | AGTACCTGAAACGGCACCCT | CTTCAAGGACAGCCAGGAAA |
| Survivin | CAGATTTGATCGGCGGACCC | CCAAGTCTGGCTTGTCAG |
| GAPDH    | ACCACTCTCTCCACTTTGAC | GTGTGCTGTAGCCAAATGTG |

Table 2. Sequences of forward and reverse primers for the genes analysed by qPCR.

Quantitative PCR analysis. Quantitative real-time PCR (qPCR) analysis was carried out to investigate the role of EgK1-1 treatment on gene expression in melanoma cells. B16-F0 cells were grown to 70% confluency in 6 well plates and treated with EgKI-1 at a concentration of 1.125 μM. 48 hours post-treatment approximately 1 × 10⁶ cells were collected by trypsinisation, washed 3 × with PBS and stored at −20 °C until use. RNA was extracted from the cells using a RNeasy mini kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Eluted RNA was then analysed by nanodrop and used to synthesise cDNA using a QuantiTect Reverse Transcription kit (QIAGEN). The cDNA samples were then stored at −20 °C for qPCR analysis.

The expression levels of the genes associated with melanoma: Matrix metalloproteinase 2 and 14 (MMP-2 and MMP-14), surviving and Bcl-2, were analysed by qPCR using the Rotor-Gene Q series software. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used as the internal standard. The sequences of the primers used are given in Table 2. Utilizing control non-treated melanoma cells as a calibrator, the relative quantitative values of target genes were expressed as 2−ΔΔCt values. Briefly, qPCR analysis was performed with 150 ng of total cDNA and QuantiNova SYBR green PCR master mix (QIAGEN) in a 20 μl reaction volume. All cDNA samples were subjected to qPCR three times using a Corbett Rotor Gene 6000 thermal cycler. Results were statistically analysed with GraphPad Prism software.

Animal ethics statement. This study was performed in strict accordance with protocols approved by the Animal Ethics Committee of QIMR Berghofer Medical Research Institute (Approval Number A1606-617M) which adheres strictly to the Australian code of practice for the care and use of animals for scientific purposes, as well as the Queensland Animal Care and Protection Act 2001, and Queensland Animal Care and Protection Regulation 2012. Mice were housed in a specific pathogen-free animal facility at the QIMR Berghofer with a 12 hours light/dark cycle and continual access to water and food.

Statistical analysis. All data are presented as the means ± standard mean of error (SEM) of three individual experiments unless otherwise stated. A p-value of <0.05 was considered as statistically significant according to the 2-way ANOVA and Student's t-tests. GraphPad Prism version 7 was used for all statistical analysis.

References
1. Australian Institute of Health and Welfare. Cancer in Australia 2017. Cancer series no. 101. Cat. no. CAN 100. Canberra: AIHW, (2017).
2. Ranasinghe, S. L., Fischer, K., Zhang, W., Gobert, G. N. & McManus, D. P. Cloning and characterization of two potent Kunitz type protease inhibitors from Echinococcus granulosus. PLoS neglected tropical diseases 9, e0004268 (2015).
3. Ranasinghe, S. L. et al. Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. PLoS one 13, e0200433 (2018).
4. Grecian, R., Whyte, M. K. B & Walmsley, S. R. The role of neutrophils in cancer. Br Med Bull 128, 5–14, https://doi.org/10.1093/bmbld/ldy029 (2018).
5. Overwijk, W. W. & Restifo, N. P. B16 as a mouse model for human melanoma. Current protocols in immunology 39, 20.21. 21–20.21. 29 (2000).

6. Fransen, M. E., Arens, R. & Melief, C. J. Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. International journal of cancer 132, 1971–1976 (2013).

7. Contreras, A. et al. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. Cancer Immunology, Immunotherapy 65, 601–611 (2016).

8. Boyle, G. M. et al. Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. PLoS One 9, e108887 (2014).

9. McKenzie, J. A. et al. Survivin promotion of melanoma metastasis requires upregulation of α 5 integrin. Carcinogenesis 34, 2137–2144 (2013).

10. Bastian, A., Nichita, L. & Zurac, S. In The Role of Matrix Metalloproteinases in Human Body Pathologies (InTech, 2017).

11. Chipuk, J. E. BCL-2 proteins: melanoma lives on the edge. Oncoscience 2, 729–730, https://doi.org/10.18632/oncoscience.193 (2015).

12. Habibie, H. et al. Survivin suppression through STAT3/β-catenin is essential for resveratrol-induced melanoma apoptosis. International journal of oncology 45, 895–901 (2014).

13. Boone, B. A. & Lotze, M. T. In Molecular Diagnostics for Melanoma 537–552 (Springer, 2014).

14. Edwards, J. et al. CD103+ tumor resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and expand significantly during anti-PD1 treatment. Clinical Cancer Research, clinicarees. 2257.2017 (2018).

15. Zhang, M. et al. T Cells derived from human melanoma draining lymph nodes mediate melanoma-specific antitumor responses In Vitro and In Vivo in human melanoma xenograft model. J Immunother 38, 229–238, https://doi.org/10.1097/CJI.0000000000000778 (2015).

16. Rao, R. M. et al. Elastase release by transmigrating neutrophils deactivates endothelial-bound SDF-1alpha and attenuates subsequent T lymphocyte transendothelial migration. J Exp Med 200, 713–724, https://doi.org/10.1084/jem.20040499 (2004).

17. Hussein, M. R. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int J Exp Pathol 87, 163–176, https://doi.org/10.1111/j.1365-2613.2006.00478.x (2006).

18. Long, K. B. & Beatty, G. L. Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology 2, e26660, https://doi.org/10.4161/onci.26660 (2013).

19. Genard, G., Lucas, S. & Michiels, C. Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Front Immunol 8, 828, https://doi.org/10.3389/fimmu.2017.00828 (2017).

20. Drexler, H. G. & Upphofer, C. C. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 39, 75–90, https://doi.org/10.1023/A:1022913015916 (2002).

21. Qiu, W. et al. Sorting and identification of side population cells in the human cervical cancer cell line HeLa. Cancer cell international 14, 3 (2014).

22. Yanarajana, M., Naranatwanchai, T., Thairat, S. & Tancharoen, S. Antiproliferative Activity and Induction of Apoptosis in Human Melanoma Cells by Houttuynia cordata Thumb Extract. Anticancer Res 37, 6619–6628, https://doi.org/10.21873/anticancer.12119 (2017).

23. Rose, S., Misharin, A. & Perlman, H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry A 81, 343–350, https://doi.org/10.1002/cyto.a.22012 (2012).

24. Riker, A. I. et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC medical genomics 1, 13 (2008).

Acknowledgements

We thank Clay Winterford in the Histology Facility at QIMR Berghofer for all the histological staining and assistance with signal detection, and the National Health and Medical Research Council of Australia for financial support.

Author contributions

S.L.R., G.M.B. and D.P.M. conceived and designed the experiments. S.L.R. and V.R. performed the experiments and analysed the data. S.L.R., G.M.B. and D.P.M. wrote the paper.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-52609-4.

Correspondence and requests for materials should be addressed to S.L.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019